Consensus-based recommendations for the management of new-onset refractory status epilepticus/febrile infection-related epilepsy syndrome
Overall, 85 recommendation statements achieved consensus. The recommendations are divided into five sections: (1) disease characteristics; (2) diagnostic testing and sampling; (3) acute treatment; (4) treatment in the post-acute phase; and (5) research, registries, and future directions in NORSE/FIRES. These are summarized in this article along with two practical clinical flowsheets: one for diagnosis and evaluation and one for acute treatment. A corresponding evidence-based analysis of all 85 recommendations alongside responses by the Delphi panel is presented in a companion article.
AE, autoimmune encephalitis; ASM, anti-seizure medication; FIRES, febrile infection-related epilepsy syndrome IV, intravenous; IVIG, intravenous immunoglobulins; NORSE, new-onset refractory status epilepticus RSE, refractory status epilepticus; SE, status epilepticus
- Wickstrom R, Taraschenko O, Dilena R, Payne ET, Specchio N, Nabbout R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection-related epilepsy syndrome (FIRES): summary and clinical tools. Epilepsia. 2022 Aug 11;63(11):2827–2839. Available at: https://onlinelibrary.wiley.com/doi/10.1111/epi.17391.